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Mouse double minute 2 (MDM2) has a phosphorylation site within a lid motif at Ser17 whose phosphomimetic
mutation to Asp17 stimulates MDM2-mediated polyubiquitination of p53. MDM2 lid deletion, but not Asp17
mutation, induced a blue shift in the λmax of intrinsic fluorescence derived from residues in the central domain
including Trp235, Trp303, Trp323, and Trp329. This indicates that the Asp17 mutation does not alter the
conformation of MDM2 surrounding the tryptophan residues. In addition, Phe235 mutation enhanced MDM2
binding to p53 but did not stimulate its ubiquitination function, thus uncoupling increases in p53 binding from its E3
ubiquitin ligase function. However, the Asp17mutation in MDM2 stimulated its discharge of the UBCH5a-ubiquitin
thioester adduct (UBCH5a is a ubiquitin-conjugating enzyme E2D 1 UBC4/5 homolog yeast). This stimulation of
ubiquitin discharge from E2 was independent of the p53 substrate. There are now four known effects of the Asp17
mutation on MDM2: (i) it alters the conformation of the isolated N-terminus as defined by NMR; (ii) it induces
increased thermostability of the isolated N-terminal domain; (iii) it stimulates the allosteric interaction of MDM2with
the DNA-binding domain of p53; and (iv) it stimulates a novel protein–protein interaction with the E2-ubiquitin
complex in the absenceof substrate p53 that, in turn, increases hydrolysis of theE2-ubiquitin thioester bond. These
data also suggest a new strategy to disrupt MDM2 function by targeting the E2-ubiquitin discharge reaction.
© 2014 Elsevier Ltd. All rights reserved.Introduction
Post-translational ubiquitination can impact upon
protein stability, turnover, specific activity, and intra-
cellular trafficking [1]. Ubiquitin attachment requires
the concerted action of an E1, initiator ubiquitin-
activating enzyme; an E2, ubiquitin-conjugating
enzyme; and an E3, ubiquitin ligase adaptor that
catalyzes the final step of ubiquitin transfer onto a
substrate [2]. E2 ubiquitin ligases can dictate the type
of ubiquitin linkage and coordinate with the E3 ligases
to play an important role in substrate selectivity [3].
E3 ligases can be divided into HECT, U box, or relay
interesting new gene (RING) domain containing pro-er Ltd. All rights reserved.tein. Unlike HECT domain ubiquitin ligases, U box
and RING domain E3 ligases do not form a covalent
bond with ubiquitin and act as a scaffold for the E2-
conjugating enzyme to catalyze the direct transfer
of ubiquitin from the E2 to the substrate [4]. The
mechanisms through which RING-containing E3
ubiquitin ligases drive E2 recognition of the substrate
and the detailed allosteric mechanisms regulating
protein–protein interaction dynamics in the ubiquitin
cascade are beginning to be defined [5,6].
The proto-oncogene mouse double minute 2
(MDM2) is a RING-domain-containing E3 ubiquitin
ligase that regulates the function of the p53 tumor
suppressor protein through diverse mechanisms,J. Mol. Biol. (2015) 427, 1728–1747
1729A Disordered Pseudo-Substrate Motif in MDM2including ubiquitination and degradation [7], repres-
sion of p53 gene transcription [8], promotion of p53
translation by binding p53 mRNA [9], and ATP-
dependent chaperone folding of p53 protein [10].
The dominant role of MDM2 as a p53 inhibitor has led
to the identification of small molecules that bind to an
N-terminal domain ofMDM2and activate p53 function
[11]. Such small molecules have recently been
evaluated in mdm2-amplified human liposarcomas
in the clinicwith partial success; themajority of patents
exhibited “stable” disease [12]. Thesedata suggest on
one hand that targeting MDM2 can begin to have
therapeutic effects in patients but the lack of a tumor
regression in the majority of patients in vivo suggests
that non-p53 companion biomarkers are required to
predict MDM2-drug-responsive patients; indeed,
MDM2 also has emerging oncogenic and “druggable”
functions that are independent of p53 [13–15].
The molecular mechanisms through which MDM2
can function as a ubiquitin ligase formabasic question
in the life sciences with an impact on concepts in
allostery, drugging protein–protein interactions, and
biomarker discovery inmdm2-driven human cancers.
MDM2 function as a ubiquitin ligase is beginning to be
dissected into distinct stages that shed light on the
contribution of each of its multiple functional domains,
an N-terminal hydrophobic p53 peptide-binding
pocket, a central intrinsically disordered domain that
regulates diverse substrate docking, and a C-terminal
RING domain that plays multiple dynamic roles in the
ubiquitination reaction mechanism [16]. The ubiquiti-
nation of p53 requires the coordinated activity of these
domains in MDM2. Initial binding of MDM2 to p53
occurs when the amino-terminal hydrophobic pocket
binds a specific sequence (the conserved FxxxWxxL
motif) within the transactivation domain of p53 [17].
The small molecule Nutlin-3 mimicking this hydropho-
bic peptide motif competes with p53 binding and
can activate p53-dependent processes in cells [11].
However, this small molecule does not inhibit
MDM2-mediated ubiquitination of p53; rather, Nutlin-3
functions as an agonist of a protein–protein interaction
between MDM2 and a second lower-affinity binding
site for p53 within the central acidic domain of MDM2
[18,19]. This second MDM2 binding site appears to
have at least one of the “ubiquitination signals” within
the flexible DNA-binding domain of p53 [20,21]: a
flexible multi-protein binding site known to contain
docking sites for several kinases that phosphorylate
the N-terminal transactivation domain of p53 at Thr18
and Ser20. Occupation of the hydrophobic pocket of
MDM2 by the p53 peptide appears to promote a more
stable interaction between the acid domain of MDM2
and the central DNA-binding domain of full-length p53,
thus forming a “dual-site” mechanism for ubiquitina-
tion of p53 [18]. More recently, the Notch receptor was
shown to be activated through a monoubiquitination
byMDM2 via a dual-sitemechanism [22]. Nutlin-3 can
also stabilize Notch protein and its downstream targetHis1 [22], aswell as promote the de-oligomerization of
NPM, providing additional evidence for an agonist
effect of Nutlin-3 on the other pro-oncogenic protein
interactions of MDM2 [23].
In addition to the apparent allosteric interaction
between the N-terminal and central domains of MDM2,
the RING domain also has unique functions in the
ubiquitination reaction. The solution structure of the
MDM2RING domain reveals a dimeric structure that
is also conserved in the MDM4 ortholog [24,25].
MDM4 can stimulate the ubiquitin ligase activity of
MDM2 protein [26] presumably by affecting RING-
dependent protein–protein interactions with E2 [27],
suggesting a dimeric structure to the RING domain
at least. Indeed, full-length, enzymatically compe-
tent MDM2 can exist as a “homo-oligomer” when
in complex to a p53 peptide using nanoparticle ag-
gregation assays and this interaction is disrupted
using peptides derived from the predicted RING
dimer interface [28]. However, the stoichiometry of
MDM2asaubiquitin ligase is not knownandemerging
structural studies will shed light on elements of its
dynamics.
Additional structure–function studies have shed
light on allosteric effects in MDM2. E3 ubiquitin ligase
inactivating mutations in the RING domain can induce
a red shift in the intrinsic fluorescence of full-length
MDM2 protein, suggesting that a conformational
change occurs in the central acidic domain where
the four tryptophan residues are clustered [29]. This
conformational change in the central domain induced
by RING mutation simultaneously increases the
binding of the N-terminal domain to p53, suggesting
that RING domain integrity can affect both central and
N-terminal domains of MDM2 [29]. In addition, a
C-terminal motif in the penultimate 9 amino acids of
MDM2 and/or MDM4 can regulate RING homo-
dimeric structure and ubiquitin ligase function [30]
highlighting another regulatory motif that can impact
on full-length MDM2 specific activity. Recent studies
have also shown that a p53 homology motif in the
central domain of MDM4 can interact with its own
N-terminal hydrophobic pocket [31] through an inter-
or intra-molecular mechanism. Related to this, recent
data have shown that the central domain of MDM2
interacts with the RING domain of the protein [32]. It is
not yet established whether theMDM2 central domain
binds to its own hydrophobic pocket since the central
domain of MDM2 does not have a “consensus”
p53-like peptide-binding motif.
The hydrophobic pocket is itself flanked by a
regulatory site; a small pseudo-substrate motif or
“lid” domain that further modulates MDM2 activity
and its interaction with p53 [33]. NMR analysis of
apo-MDM2 suggests that the pseudo-substrate motif
is highly flexible with the potential to adopt several
positions and conformations around MDM2's N-
terminal region and hydrophobic pocket. This in-
cludes a “closed” conformation where the motif acts
1730 A Disordered Pseudo-Substrate Motif in MDM2similar to a lid covering the hydrophobic pocket and
is thought to occlude substrate binding. In another
conformation, the pseudo-substrate motif folds away
from the pocket leaving the hydrophobic binding
cleft exposed and in an “open” conformation with(a) (b)
(d) (e)
(g) (h)
(j)
Fig. 1 (legend oincreased p53 binding activity [34]. A potential
DNA-PK phosphorylation site was identified within
the pseudo-substrate motif at Ser17; however, its
function in cells is not clear [35]. NMR studies of
apo-MDM2 suggested that phosphorylation at this(c)
(f)
(i)
n next page)
1731A Disordered Pseudo-Substrate Motif in MDM2site Ser17 would drive the lid over the hydrophobic
pocket preventing substrate access and destabiliz-
ing p53 binding [34]. However, biochemical analyses
suggest that phosphomimetic mutation of Ser17
actually enhances the charge interactions between
the lid motif and the hydrophobic patch of residues
(Arg97 and Lys98) on the surface of the N-terminal
lobe. This is thought to lock the lid in the open
conformation and increase substrate access to the
hydrophobic pocket [36,37]. Enzymatic analyses
confirmed this hypothesis as phosphomimetic mu-
tation of MDM2 at Ser17 enhanced MDM2 binding
to p53 and increased p53 ubiquitination in vitro while
substitution of Arg97 and Lys98 within the hydro-
phobic patch thought to bind phospho-Ser17 negat-
ed the positive effects of Asp17 mutation [36].
Biophysical analyses revealed that phosphomimetic
mutation of Ser17 within the N-terminal region of
MDM2enhanced its thermodynamic stability highlight-
ing an altered protein conformation induced by theAsp
mutation [38]. Together, these data indicate that the
pseudo-substrate or lidmotif has a significant effect on
the structure and function of MDM2 and suggests that
allosteric communication occurs between the lid
domain and the central domain of MDM2.
In this study, we analyze the mechanism in more
detail whereby the Asp17 mutation stimulates the
ubiquitin ligase activity of MDM2 toward p53. Our
findings suggest that allosteric alterations resulting
from phosphorylation of MDM2 at Ser17 could regulateFig. 1. The development of a phospho-specific mAb to access
Generation of a phospho-Ser17-specificmAb. Hybridomas genera
with the amino acid sequence 14-Val-Thr-Thr-(Ser-phospho17)-
hybridomaswere screened by dot-blot (data not shown) [39] and a
one mAb named EW102 (RLU) is plotted as a function of pe
derivatives (in b)]. (c) Definition of the consensus epitope for E
combinatorial library to determine whether the core epitope forms
three rounds of phage screening, peptide sequenceswere identifie
homology. The key elements of the epitope include a hydrophili
epitope flankingSer17andahydrophobicmotif (Gln/Tyr/Trp/Phe)
(d) High cell density increases in vivo phosphorylation of MDM
subjected to growth at three different time point reflecting change
respectively). Cells were lysed and processed for immunoblotting
and β-actin. (e) The effects of MG132 on phospho-Ser17 MDM2
indicated, and they incubate without or with the proteasome inhibit
processed for immunoblotting for Ser17-phospho MDM2, total MD
MDM2at elevated cell density can be recapitulated byectopic expre
MDM2 when cells were at 100% (lanes 2–5) or 40% confluency
incubated with cycloheximide to define changes in half-life. Cells
protein and β-actin. (g) The effects of cell density on ectopically e
transfect EGFPwhen cellswere at 100%, 80%, and40%cell densi
lysed and processed for immunoblotting for total EGFP protein and
Asp17-MDM2. An expression vector for Asp17-MDM2was used to
cell density, as indicated. Twenty-four hours post-transfection, cells
protein and β-actin. (i) The effects of cell density on ectopically expr
to express theproteinwhencellswereat 100%,80%,and40%cell
were lysed and processed for immunoblotting for total MDM2 p
ectopically expressed wt-MDM2 and Asp17-MDM2. A titration of t
was performed to define the steady levels without or with proteaso
incubated with MG132 for 2 h, lysed and processed for immunoblRING-domain-mediated E2 UBCH5a-ubiquitin dis-
charge (UBCH5a is a ubiquitin-conjugating enzyme
E2D 1 UBC4/5 homolog yeast) that accelerates E2
cycling and increased p53 substrate polyubiquitination.
This might be an important mechanism in solid tumors,
since we also show a high-cell density-dependent
increase in MDM2 phosphorylation at Ser17 in cell
lines.Results and Discussion
Does the Asp17-MDM2 mutant represent a physio-
logically relevant tool to study allostery in MDM2?
Phosphorylation at the PI3K site of MDM2 at
Ser17 was identified in cells using a phospho-specific
polyclonal antibody [35]; however, the regulation of
phosphorylation at this site in cells and the effects on
the biochemical activity of MDM2 are not well defined.
In addition, the kinase that targets this site in cells
is not well defined. We aimed to develop a more
rigorous evaluation of this phospho-acceptor site in
cell systems to define whether it might have possible
effects on MDM2 activity in cells. In turn, this would
inform whether or not the phosphomimetic Asp17-
MDM2 mutant would be a relevant tool to evaluate
MDM2 function as a ubiquitin ligase in a reconstituted
multi-component in vitro system.in vivo signaling to Ser17 on humanMDM2 protein. (a and b)
ted from immunization of aKLH-conjugated synthetic peptide
Gln-Ile-Pro-Ala-Ser-22 derived from the MDM2 lid. Positive
representative ELISA showing phospho-peptide specificity of
ptide used [wt-phospho-Ser17 peptide or alanine mutated
W102. Purified mAb was processed using a peptide-phage
a homology motif with the bona fide lid motif in MDM2. After
d [40] andprocessed by pblast to identify possible consensus
c/acidic motif (Ser/Thr/Asp/Glu) on the N-terminal half of the
that isC-terminal to theother half of theepitope flankingSer17.
2 at Ser17. A375 cells containing a wt-p53 pathway were
s in cell density (40%/80%/100% confluency for days 1/2/3,
for Ser17-phospho MDM2, total MDM2 protein, p53 protein,
levels. Cells were processed when at low or high density, as
or MG132 (50 μM for 4 h), as indicated. Cells were lysed and
M2 protein, and β-actin. (f) The reduced steady-state levels of
ssion. Expression vectors forwt-MDM2wereused to transfect
(lanes 6–9). Twenty-four hours post-transfection, cells were
were lysed and processed for immunoblotting for total MDM2
xpressed EGFP. An expression vector for EGFP was used to
ty, as indicated. Twenty-four hours post-transfection, cellswere
β-actin. (h) The effects of cell density on ectopically expressed
express the protein when cells were at 100%, 80%, and 40%
were lysed and processed for immunoblotting for total MDM2
essedwt-MDM2. An expression vector for wt-MDM2was used
density, as indicated. Twenty-four hourspost-transfection, cells
rotein and β-actin. (j) The effects of MG132 on the levels of
he expression vectors encoding wt-MDM2 and Asp17-MDM2
me inhibition. Twenty-four hours post-transfection, cells were
otting for total MDM2 protein and β-actin.
1732 A Disordered Pseudo-Substrate Motif in MDM2A phospho-specific monoclonal antibody (mAb) was
developed by immunizing mice with a phospho-Ser17
peptide conjugated to KLH and selecting hybridomas
that secrete a specific mAb. The phospho-specificity
of the mAb (EW102) is shown in Fig. 1a (CON) [wt
(wild-type) phospho-peptide versus non-phospho-
peptide]. Alanine-substituted mutation of the synthetic
phospho-peptide at positions (Fig. 1b) attenuates the(a)
(c)
(e)
(f) (g)
(d)
(b)
Fig. 2 (legend on next page)binding of the EW102 mAb to the phospho-peptide
(Fig. 1a): most notably, at Thr16, Ile19, and Pro20. A
phage-peptide library was used to acquire a
“consensus site” for EW102 (Fig. 1c) wherein a
phospho-acceptor site (Ser) or a phosphomimetic
mutation (Asp or Glu) was selected at the Ser17-
equivalent position (in blue). In addition, there was a
strong selection for a Gln at position 18 (in green) and
1733A Disordered Pseudo-Substrate Motif in MDM2hydrophobic amino acids (Ile, Try, Phe, Gly, Ala) at
position equivalent to codon 19 (in yellow). Together,
these data are consistent with the generation of a mAb
with phospho-specificity andwith an epitope containing
homology to MDM2 protein.
Using EW102, we were unable to observe any
changes in MDM2 Ser17 phosphorylation after DNA
damage to cells (data not shown). DNA damage in
the form of UV or ionizing radiation is the normal
“stress” used to impact on the p53 pathway [41].
However, we did observe a reproducible increase in
MDM2 phosphorylation at Ser17 with an inverse
correlation with MDM2/p53 protein steady-state
levels when cell density was elevated in A375 cells
(wt-p53 pathway) (Fig. 1d). This “attenuation” in p53
protein levels at higher density is consistent with a
prior observation that p53 pathway activity is
suppressed at the high cell density presumed to
operate in vivo in human cancers [42]. We also
evaluated whether this density-dependent phos-
phorylation could be observed in another cell line;
we used HCT116 since this cell line is well
characterized with respect to wt-p53 regulation and
function [43]. As in A375 cells, the basal levels of
total MDM2 protein are reduced at high cell density
(Fig. 1e, lane 3 versus lane 1). The basal phosphor-
ylation of MDM2 at Ser17 seen at high cell density
(Fig. 1e, lane 3 versus lane 1) was elevated with the
addition of MG132 (Fig. 1e, lane 4 versus lane 3).
This suggests that the pool of phospho-Ser17 MDM2
undergoes increased degradation rates at high cell
density by a ubiquitin-dependent pathway but that
less Ser17 phosphorylation occurs when cell are
cycling at low density.
We next determined whether ectopically
expressed MDM2 protein could mimic endogenous
MDM2 protein changes in its half-life as a function of
cell density. A transfection of wt-MDM2 at 40% andFig. 2. The Asp17 mutation in MDM2 selectively stimulates
was purified as indicated in Experimental Procedures; norm
electrophoresis using Coomassie blue. (b) The effects of pol
Asp17-MDM2. The indicated proteins were assembled using
Asp17mutation increases the polyubiquitination or monoubiqu
15 min using ubiquitin-specific antibodies FK2 (that detects
(that exhibits specificity for polyubiquitination). (c–e) Optim
Ubiquitination assays were assembled as indicated in Exp
Asp17-MDM2. Reactions were stopped and immunoblotted us
monomeric p53, multi-monoubiquitination of p53, or polyubiquitin
Asp17-MDM2onp53ubiquitination for fixed time; (d) the effects of
or Asp17-MDM2; (e) the effects of changing p53 protein levels o
Asp17-MDM2. (f andg)DeterminingwhetherAsp17-MDM2canca
Conceptual outline of the approach to trap p53 protein, after ubi
CM-1 attached to the solid phase and measuring the extent o
antibodies FK1 or FK2. (G) Ubiquitination assays were assembled
wt-MDM2orAsp17-MDM2, optimizedp53, andoptimized time, as
a final volumeof 50 μl using PBS-Tween-20 (0.1%) and incubated
to trap the reaction products. The wells were then washed with P
(FK1or FK2) and thendevelopedusing theHRP-conjugated seco
data are plotted as extent of p53 ubiquitination (RLU) as a functio100% cell confluency followed by a cycloheximide
chase demonstrates that MDM2 basal levels are
lower at high density and that the turnover is more
rapid (Fig. 1f). We next asked whether the Asp17
mutation in ectopically expressed MDM2 sensitized
it to enhanced degradation in cells. As a control, the
transfection of a vector expressing GFP (green
fluorescent protein) did not result in changes in
GFP levels as a function of cell density (Fig. 1g). By
contrast, both ectopically expressed wt-MDM2 and
Asp17-MDM2 exhibited decreased steady-state
levels at higher cell density and the Asp17-MDM2
mutant in turn had a lower steady-state ratio (low
density versus high density) level than wt-MDM2
(Fig. 1h and i). The lower levels of ectopically
expressed MDM2 or Asp17-MDM2 proteins at high
density appear to be through enhanced degradation
since MG132 rescued ectopically expressed MDM2
protein loss (Fig. 1j). Together, these data demon-
strate that, in cells, the artificially constructed
Asp17-MDM2 and the endogenous phospho-
Ser17-MDM2 are similarly responding to degrada-
tion signals at elevated cell density. As such, we
continued to use this Asp17-MDM2 mutant as a
physiologically relevant mimetic to dissect mecha-
nisms of allosteric control in E3 ubiquitin ligaseMDM2
function in vitro that builds upon this prior biochemical
characterization.
Optimization of an in vitro reconstituted
ubiquitination assay using Asp17-MDM2
In order to access the mechanism where the
Asp17-MDM2 mutant catalyzes enhanced ubiquiti-
nation of p53 [36], we reconstituted a system with
purified proteins (Fig. 2a). A ubiquitination reaction
using equal amounts of wt-MDM2 and Asp17-
MDM2, in the absence or presence of p53,polyubiquitination of p53. (a) Purification of MDM2. MDM2
alized amounts were quantified using Bradford and by
yubiquitination chain assembly catalyzed by wt-MDM2 or
in vitro ubiquitination reactions to determine whether the
itination function of MDM2. Samples were processed after
both monoubiquitination and polyubiquitination) and FK1
ization of Asp17-MDM2 catalyzed ubiquitination of p53.
erimental Procedures, with the indicated wt-MDM2 or
ing a p53 mAb. The reaction products highlighted include
ation of p53. (c) The effects of changing levels of wt-MDM or
changing the time of ubiquitination of p53 using fixedwt-MDM
n p53 ubiquitination for fixed time and using fixed wt-MDM or
talyzeenhancedp53ubiquitinationusingap53 trapassay. (f)
quitination, using the p53-affinity-purified polyclonal antibody
f p53 ubiquitination using the ubiquitin-specific monoclonal
as indicated in Experimental Procedures, with the optimized
identified from (c) to (e) (seeabove).Reactionswerediluted to
inwells containing the p53-specific rabbit polyclonal antibody
BS-Tween-20 (0.1%), incubated with the primary antibodies
ndary antibodies to quantify theubiquitin adducts present. The
n of MDM2 isoform used.
1734 A Disordered Pseudo-Substrate Motif in MDM2demonstrated that the Asp17-MDM2 protein in-
creases total polyubiquitination using an anti-ubiqui-
tination antibody set (Fig. 2b, lane 10 versus lane 9).
The reason why we exclude p53 is to determine
whether the effect of the S17D mutation on MDM2
can be independent of the p53 substrate—if so, it
would simplify dissection of the reaction mechanism
(see Fig. 7, E2-ubiquitin discharge reactions that are
also p53 independent; e.g., therefore, the effects of
the S17D mutation are intrinsic to MDM2). A titration
of wt-MDM2 and Asp17-MDM2 at a fixed time point
confirms that polyubiquitination of p53 is enhanced
by the Asp17-MDM2 enzyme, relative to wt-MDM2
(Fig. 2c, from 25 to 50 ng MDM2 protein). The rates
of multiple p53 monoubiquitination (the three adducts
highlighted 1, 2, and 3) appears relatively similar using
either MDM2 isoform (Fig. 2c). Using fixed amounts
of MDM2 over a time course from 5 to 20 min, it is
similarly demonstrated that Asp17-MDM2 is more
able to catalyze p53 polyubiquitination (Fig. 2d). The
enhanced ubiquitination of p53 by Asp17-MDM2 at
fixed E3 ubiquitin ligase levels and a fixed time could
beobserved from20 to 100 ngof p53 protein (Fig. 2e),
while 10 ng of p53 or lower did not reveal a significant
difference in rates of polyubiquitination by wt-MDM2
or Asp17-MDM2. We also evaluated the extent of
differences in p53 ubiquitination by capturing p53
protein in its native state on the solid phase with a
polyclonal antibody (CM-1) after ubiquitination reac-
tionswere completed (Fig. 2f). This assay also reveals
that Asp17-MDM2 catalyzes enhanced ubiquitination
using polyubiquitin chain-specific antibody (FK1) or
mixed monoubiquitin/polyubiquitin chain-specific an-
tibody (FK2) (Fig. 2f), consistent with data in Fig. 2c.
The data together demonstrate that Asp17-MDM2Fig. 3. The Asp17 mutation desensitizes MDM2 to p53 prot
docking sites in the p53 central domain. The central domain o
sites, including a mAb (DO-12) that binds to “unfolded” or “dena
ubiquitination [18], and DAPK/Aurora Kinase phospho-accept
DNA on p53 ubiquitination by Asp17-MDM2. P53 consensus sit
p53, suggesting that conformational changes open acetyltransf
protein with consensus site DNA (from 10, 20, 40, and 80 ng, lef
suggesting that the central domain docking site becomes cryptic
maintains the ability to drive p53 ubiquitination in the presence
denaturation of p53 on its ubiquitination by Asp17-MDM2. Ub
Procedures, using the E3 ubiquitin ligases wt-MDM2 (lane 1
assembling reactionswith p53 at 4 °C (lanes 1–3), reactionswer
Reactions were stopped and immunoblotted using a p53 mAb.
multi-monoubiquitination of p53, or polyubiquitination of p53. (d) C
by reactivity to conformational-specific mAbs. P53 from the rea
to define the ratio of PAB1620 (folded) to PAB240 (unfolded
(e) Conformationally wt-p53 or mutant “unfolded” conformat
Ubiquitination assays were assembled as indicated in Experim
Asp17-MDM2, and CHIP, except that p53 was synthesized us
pCDNA3.1. Reactions were stopped and immunoblotted usin
monomeric p53, multi-monoubiquitination of p53, or polyubiquit
indicated inExperimental Procedures, using theE3ubiquitin ligas
mutant series was used, as indicated. Reactions were stopped a
highlighted include monomeric p53, multi-monoubiquitination ofpromotes a higher extent of p53 polyubiquitination
than wt-MDM2 (Fig. 2g).
The effects of p53 conformation on
ubiquitination by Asp17-MDM2
MDM2 has at least two binding sites on p53: one in
the N-terminal activation domain [17–26] [44] and
the second one in the DNA-binding domain within
the conformationally flexible epitope from 269 to 280
(Fig. 3a) [18,19]. We next evaluated how the central
domain conformation of p53 can affect its recognition
by wt-MDM2 and Asp17-MDM2. Previous data
demonstrated that DNA could suppress the con-
formationally sensitive mAb DO-12 epitope from
260 to 280 on p53 [49]. We asked whether a similar
suppression of MDM2 binding could be observed
and whether the Asp17 mutation altered the effects
of MDM2 on p53 ubiquitination when p53 is DNA
bound. Increasing amounts of DNA suppresses
ubiquitination of p53 by wt-MDM2 (Fig. 3b, lanes
2–6) consistent with the concept that it suppresses
the exposure of this region on p53 when p53 binds
DNA. However, the Asp17-MDM2 enzyme is insen-
sitive to DNA (Fig. 3b, lanes 7–11). This is consistent
with data showing that Asp17-MDM2 exhibits an
elevated affinity for its second binding site in the p53
DNA-binding domain [36].
The requirement for a “native” p53 conformation to
prime it for ubiquitination by MDM2 is further implied
because the heating of p53 can attenuate the rate
of its polyubiquitination by MDM2, as well as the
ubiquitin ligase CHIP (Fig. 3c). CHIP was used as a
“control” p53 ubiquitin ligase since it is, like MDM2,
able to stimulate p53 ubiquitination and act as aein ubiquitination conformational constraints. (a) Review of
f p53 has a conformationally flexible set of protein docking
tured” p53 [45], an MDM2 docking motif that stimulates p53
or sites that unfold p53 protein [46,47]. (b) The effects of
e DNA is known to stimulate DNA-dependent acetylation of
erase motifs [48]. Consistent with this, the incubation of p53
t to right) can suppress ubiquitination by MDM2 (lanes 3–6),
for MDM2 (as with DO-12 [49]). By contrast, Asp17-MDM2
of consensus site DNA (lanes 8–11). (c) The effects of heat
iquitination reactions were assembled as in Experimental
), Asp17-MDM2 (lane 2), and CHIP (lane 3). Instead of
e preincubated at 37 °C (lanes 5–8) or at 42 °C (lanes 9–12).
The reaction products highlighted include monomeric p53,
ontrols demonstrating that heating “unfolds” p53 as defined
ction in (c) (above) was subjected to immunoprecipitation
) conformation, using methods previously published [21].
ional variants were accessed in ubiquitination reactions.
ental Procedures, using the E3 ubiquitin ligases wt-MDM2,
ing rabbit reticulocyte lysates with the indicted p53 allele in
g a p53 mAb. The reaction products highlighted include
ination of p53. (f) Ubiquitination assays were assembled as
eswt-MDM2,Asp17-MDM2, andCHIP, except that ubiquitin
nd immunoblotted using a p53 mAb. The reaction products
p53, or polyubiquitination of p53.
1735A Disordered Pseudo-Substrate Motif in MDM2chaperone on p53 [50]. The extent of monoubiqui-
tination is not so strikingly attenuated after p53
heating, however. As controls, we show that the
heating of the p53 at 37 °C and 42 °C does indeed
increase the amount of “unfolded” p53 as defined by
increased binding to the denaturation-specific mAb(a) (b)
(c)
(d) (e)
(f)
Fig. 3 (legend onPAB240 (Fig. 3d, lanes 4, 8, and 12). Accordingly,
increasing the temperature also reduces the amount
of “folded” p53 as defined by decreased binding to
the wt conformationally specific mAb PAB1620
(Fig. 3d, lanes 3, 7, and 11). As heat denaturation of
p53may not be a physiological approach to produce aprevious page)
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characterized phosphomimetic mutation in the
DNA-binding domain that is known to produce an
“unfolded” or mutant conformation on p53 [46,51].
Inactivating mutation of p53 through the Asp269
mutation decreases the extent of p53 ubiquitination
using either wt-MDM2 or Asp17-MDM2 (Fig. 3e).
However, Asp17-MDM2 is still able to catalyze
monoubiquitination of Asp269-p53 (Fig. 3e, lane 11),
which is again consistent with the increased affinity of
Asp17-MDM2 for its binding site in the p53 DNA-
binding domain.
We finally examined how ubiquitin mutants can
affect Asp17-MDM2 use as a cofactor in p53 ubiqui-
tination as ameasure of the robustness of themutation
on MDM2 function. The Ub-Arg48 mutant can still be
conjugated to p53 to create a polyubiquitination chain
when using wt-MDM2, Asp17-MDM2, or CHIP (Fig. 3f,
lanes 1–4). The Ub-Lys48-only form of ubiquitin could
be used essentially only to promote multiple mono-
ubiquitination of p53 when using wt-MDM2,
Asp17-MDM2, or CHIP (Fig. 3f, lanes 5–8). Similarly,
the Ub-Arg63 mutant can still be conjugated to p53 to
create a polyubiquitination chain when using
wt-MDM2, Asp17-MDM2, or CHIP (Fig. 3f, lanes 9–
12), but the Ub-Arg63-only form of ubiquitin could be
used essentially only to promote multiple monoubiqui-
tination of p53 when using wt-MDM2, Asp17-MDM2,
or CHIP (Fig. 3f, lanes 13–16). In the latter situation,
again Asp17-MDM2 had an increased specific activity
relative to wt-MDM2 (Fig. 3f, lanes 10 and 11). These
data also highlight the enhanced specific activity of
Asp17-MDM2 as a ubiquitin ligase, compared to
wt-MDM2, on a set of artificial ubiquitin mutants.
Dissecting the mechanism of enhanced MDM2 E3
ubiquitin ligase function through Asp17mutation:
The Asp17 mutation does not induce a change in
the intrinsic fluorescence of MDM2
In order to dissect the mechanism underlying the
effects of the Asp17 mutation on enhanced ubiqui-
tination of p53, we set out to determine whether
the Asp17 alters the conformation of MDM2 using
biophysical approaches. Using purified componentsFig. 4. The effects of lid deletion or Asp17 mutation on t
Asp17-MDM2 was titrated into reactions containing (a) p53 on t
solid phase. The amount of MDM2 bound was detected with an
The data are plotted as the amount of MDM2 bound (RLU) as a
suggests that the lid motif might alter intrinsic fluorescence med
of MDM2. (d) A prior report highlighted that RING domain mut
correlates with increase p53 binding [29]. The experiment is
mutation alters intrinsic fluorescence. (e) The fluorescence emi
λmax of fluorescence and the total fluorescence (right). (f) The m
of fluorescence and whose deletion causes a “blue shift” from
finger) that correlates with reduced binding to p53 [36,38]. By co
of fluorescence, and as such, increased binding of Asp17-M
changes in the tryptophan residues in the central MDM2 domaof the ubiquitination reaction, we confirm that the
Asp17 mutation induces a more stable binding of
MDM2 to p53 (Fig. 4a), without similarly affecting
stable binding to E2 (UBCH5a) (Fig. 4b). UBCH5a
was used as it represents the dominant E2 ubiquitin
ligase for p53 in cells [52]. One possible mechanism
to explain how the Asp17 mutation stimulates
MDM2-mediated ubiquitination of p53 is simply that
it increases the interaction of the central acidic
domain of MDM2 for p53 [36]. MDM2 protein has
four internal tryptophan residues (Fig. 4c) that could
mediate intrinsic fluorescence of the protein follow-
ing excitation at 295 nm and recording emission
spectra from 320 nm to 395 nm. It can be relatively
difficult to dissect the contribution from individual
tryptophan residues when there is more than one,
without many mutants being generated and with
complex lifetime studies. However, if λmax shifts,
then we can be confident that the conformation/
dynamics have changed. While if λmax does not
change significantly, then there could be important
protein changes but there could also be compensa-
tory effects that mask the combined fluorescence
output.
We evaluated whether, indeed, the Asp17 muta-
tion can alter the central domain conformation as
monitored through changes in intrinsic fluorescence.
It is generally held that the λmax in the emission
spectrum of tryptophan will be shifted to shorter
wavelengths (blue shifted) if the tryptophan be-
comes more involved (“buried”) within a hydrophobic
environment while a shift to longer wavelengths (red
shifted) can occur if the tryptophans interact more
with the aqueous buffer through hydrogen bonding;
this assay was used previously to demonstrate that
certain RING domain mutations in MDM2 can induce
a red shift in the intrinsic fluorescence that coincides
with an increase in MDM2 affinity for N-terminal
ligands such as Nutlin-3 and increased transrepres-
sion of p53 [29]. This latter study provided the first
biophysical evidence that RING domain integrity
can alter the conformation of both the central domain
(containing the four tryptophan residues) and the
N-terminal domain in a concerted fashion. When
wt-MDM2 and Asp17-MDM2 were subjected tohe intrinsic fluorescence of MDM2 protein. wt-MDM2 or
he solid phase or (b) the E2 ubiquitin ligase UBCH5a on the
MDM2 antibody as indicated in Experimental Procedures.
function of changes in MDM2 protein levels. (c) One model
iated by the four tryptophan residues in the central domain
ations increase the λmax of fluorescence and this red shift
designed to determine whether the lid deletion or Asp17
ssion spectra of the indicated MDM2 proteins (left) with the
odel highlighted that the lid motif maintains a specific λmax
the tryptophan residues (in the acidic domain and the zinc
ntrast, the Asp17mutation has no detectable effect on λmax
DM2 to p53 [36] cannot be explained by environmental
in.
1737A Disordered Pseudo-Substrate Motif in MDM2excitation–emission (as in Fig. 4d), there was no
discernable change in intrinsic fluorescence (λmax of
both was 348.5 nm). This would suggest that the(a)
(c)
(e)
(f)
Fig. 4 (legend onincreased binding of Asp17-MDM2 to p53 (Fig. 4a) is
uncoupled from conformational changes linked to
intrinsic fluorescence. By contrast, the deletion of the(b)
(d)
previous page)
(a)
(b)
(c)
(d)
Fig. 5. The effects of the Phe235 mutation on the intrinsic fluorescence of MDM2. (a) Amino acid sequence of the “central
domain” ofMDM2 containing the “acidic domain” and the “zinc-finger” domain. (b and c) The fluorescence emission spectra of
the indicated MDM2 proteins (left) with the λmax of fluorescence and the total fluorescence (right). The Phe235 mutation
induces the same 4-nm blue shift in the λmax of fluorescence whether in the context of wt-MDM2 or the lid deletion MDM2
mutant. (d)With the use of the tryptophan-to-phenylalanine codon 235mutant, themodel highlights that the lidmotif maintains
a specific λmax of fluorescence and whose deletion in Phe235-MDM2 causes the same “blue shift” from the tryptophan
residues (in zinc finger) that correlates with reduced binding to p53 [36,38].
1738 A Disordered Pseudo-Substrate Motif in MDM2MDM2 lid (which renders MDM2 temperature sensi-
tive for p53 ubiquitination [36] and for ligand binding
[38]) induces a blue shift in the intrinsic fluorescence(Fig. 4d), suggestive of a “closed and inactive”
conformation. The increase in total fluorescence
also is indicative of more “buried” tryptophans.
(b)
(a)
(c)
(d)
Fig. 6. The effects of the Phe235mutation on the biochemical activity of MDM2. (a–c) p53 binding reactions were assembled
as indicated previously, with the conceptual format on the right of each panel: (a) MDM2 binding to full-length p53, (b) MDM2
binding to the BOX-I peptide motif of p53 (Biotin-SGSGPPLSQETFSDLWKLLP), and (c) MDM2 binding to the BOX-V peptide
motif of p53 (Biotin-SGSGRNSFEVRVCACPGRD). Each binding reaction was performed by titrating the indicated MDM2
protein on fixed p53 protein and the binding of MDM2 was detected using an anti-MDM2 antibody and an HRP-conjugated
secondary antibody. The data are plotted asMDM2activity (RLU) as a function ofMDM2protein amounts (ng). (d) Ubiquitination
assays were assembled as indicated in Experimental Procedures, with the indicated MDM2 isoforms. Reactions were stopped
and immunoblotted using a p53 mAb. The reaction products highlighted include monomeric p53 or polyubiquitination of p53.
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1740 A Disordered Pseudo-Substrate Motif in MDM2These data indicate that although the lid motif of
MDM2 impacts on the conformational integrity of the
central domain, the Asp17 mutation does not impact
on this property of MDM2 (Fig. 4e). Thus, the
stimulatory effect of the Asp17 mutation is not due
to alteration in the solvent interaction of the Trp
residues in the central domain of MDM2.
To further clarify this effect, we mutated the only
tryptophan in the “acidic domain” to phenylalanine
(Trp235 to Phe235-MDM2) leaving all remaining
tryptophan residues to the zinc finger (Fig. 5a). The
Phe235-MDM2 mutation induces a 4-nm blue shift in
the λmax of emission relative to wt-MDM2 (Fig. 5b). In
addition, whether or not the MDM2 lid is present
(Fig. 5b and c), the Phe235 mutation induces a 4-nm
blue shift in the λmax of emission. These data
suggest that Trp235 is relatively more solvent
exposed and contributes a longer wavelength
emission than the Zn-finger tryptophan residues.
These data also suggest that the lid motif can
specifically alter the conformation of the zinc-finger
domain (if not the “acidic domain”) (Fig. 5d).
Using this new panel of MDM2 mutants, we asked
whether the increased ubiquitin ligase activity of
Asp17-MDM2 was linked to the ability of the
mutations to increase binding to p53 protein. The
Phe235 mutation in MDM2 increased binding of
MDM2 to p53 (Fig. 6a), marginally increased binding
of MDM2 to the BOX-I motif of p53 (from the
N-terminal domain of p53) (Fig. 6b) and substantially
stimulated the binding of MDM2 to the BOX-V motif
of p53 (from the central domain of p53) (Fig. 6c). By
contrast, deletion of the MDM2 lid reduced binding to
p53 (Fig. 6a), marginally reduced binding of MDM2
to the BOX-I motif (Fig. 6b), but formed a synthetic
lethal interaction with the Phe235 mutation that
almost completely inactivated the binding of the
protein to the BOX-V motif (Fig. 6c). Although these
data provide more biophysical evidence for an
allosteric interaction between the MDM2 lid and the
central domain of MDM2, the Phe235 mutation did
not have increased ubiquitin ligase activity (Fig. 6d).
Thus, despite the fact that the MDM2 lid itself can
mediate an allosteric interaction affecting the central
domain conformation, we have uncoupled increased
binding of MDM2 to the central domain of p53 from
direct increases in p53 ubiquitination. That is (as inFig. 7. The effects of the Asp17 mutation in MDM2 on E2-u
MDM2asa functionof (i) lid deletion, (ii) Phe235mutation, or (iii) A
an E2-ubiquitin discharge assay. (c) Production of a stable E2-ub
with ubiquitin resulting in a stable adduct (UBCH5a-Ub) over 30 m
mutation on E2-ubiquitin discharge. Following the production o
wt-MDM2 (lanes 2–7) or Asp17-MDM2 (lanes 8–12) followed by i
for measuring extent of ubiquitin discharged from E2 and quan
catalyzed discharge of ubiquitin from E2. The full ubiquitination r
that the reactions contain no p53, low p53, or high p53. The indic
the indicated times and reactions processed to measure the extFig. 7a), (i) theAsp17mutation increases ubiquitination
of p53 but not through alterations in central domain
conformation (as defined through intrinsic fluores-
cence), and (ii) the Phe235 mutation increases the
binding to the central domain of p53, but this mutation
does not increase p53 ubiquitination. How, then, does
the Asp17 mutation increase p53 ubiquitination if not
simply through enhanced binding to p53 or through
altering the central domain conformation of MDM2?
The Asp17 mutation in MDM2 stimulates E2-
ubiquitin thioester hydrolysis
Apart from the interaction of the N-terminal domain
and the central domain of MDM2 with p53 protein, the
other major protein–protein interactions are between
the RING domain with itself and between the RING
domain and the E2-ubiquitin conjugation enzyme
UBCH5a [27]. As such, we evaluated whether the
Asp17 mutation has any affects on UBCH5a ubiquitin
charge or discharge reaction that would in turn explain
how the mutation stimulates MDM2 function as an E3
ubiquitin ligase. The ubiquitin discharge reaction is
emerging another key step in the phospho-transferase
reaction. Although there is very little experimental data
on the E2-ubiquitin discharge reaction, a recent study
highlighted the discovery of a small molecule that
interfered with the discharge of ubiquitin from human
CDC34 to acceptor lysine residues in substrates
catalyzed by the cullin-RING family of E3 ubiquitin
ligases [53,59]. To our knowledge, there has been no
study evaluating E2-ubiquitin discharge by MDM2
using purified components.
We staged the charging of E2 ubiquitin ligase with
ubiquitin by optimizing E1 and E2 concentrations
(data not shown; Fig. 7b) that result in an E2-ubiq-
uitin conjugate that is stable for at least 30 min in
reaction buffer (Fig. 7c, lanes 2–7). MDM2 did not
affect the rate of E1 or E2 charging with ubiquitin
(data not shown). However, addition of wt-MDM2
induces a discharge of the ubiquitin-E2 adducts from
approximately 20–30 min (Fig. 7d, lanes 5–7), while
the Asp17 mutation stimulates this from as little as
10 min onward (Fig. 7d, lanes 9–12, and Fig. 7e).
The discharge of ubiquitin from E2 by MDM2 was
independent of the end substrate ubiquitin acceptor,
p53, using either wt-MDM2 (Fig. 7f) or thebiquitin discharge. (a) Summary of biochemical effects on
sp17mutation. (b) Summaryof stages in the development of
iquitin thioester adduct. Reactions were set up to charge E2
in of a reaction at 30 °C. (d) The effects of the Asp17-MDM2
f charged E2-ubiquitin adducts [as in (c)], we added fixed
ncubation for the indicated times. Reactionswere processed
titated in (e). (f and g) The effects of p53 protein on MDM2
eactions were set up to fully charge E2 with ubiquitin, except
ated wt-MDM2 [in (f)] or Asp17-MDM2 [in (g)] was added for
ent of E2-ubiquitin discharge.
1741A Disordered Pseudo-Substrate Motif in MDM2Asp17-MDM2 mutant (Fig. 7g). The ability if the
Asp17 mutation to stimulate the discharge of
ubiquitin from E2, in a manner that is p53 indepen-(a)
(b)
(c) (d)
(e) (f)
(g)
Fig. 7 (legend ondent (Fig. 7e and f) suggests that the Asp17 mutation
can affect the interaction of MDM2 with either the
ubiquitin or the E2 component in the reaction.previous page)
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The E3 ubiquitin ligase MDM2 is a multi-domain
pro-oncogenic protein proving to be a compelling
anti-cancer drug target in human cancer [12]. One
key druggable domain of MDM2 contains a pepti-
de-binding pocket able to interact with a peptide
motif in the p53 tumor suppressor and has been the
subject of drug discovery programs for almost
20 years. Small molecules that bind to this N-termi-
nal hydrophobic pocket of MDM2 can activate p53,
but they do not inhibit the E3 ubiquitin ligase activity
of MDM2; rather, occupation of this pocket by small
ligands can function as an allosteric effector and
modify MDM2 protein interactions [18]. This partial
agonist effect of Nutlin-3 class of molecules on
MDM2 protein–protein interactions might explain in
part the inability of such MDM2 ligands to induce
tumor regression in the majority of patients with a
wt-p53/MDM2 amplified genotype, in a recent clinical
trial [12]. As such, better characterization of full-length
MDM2 in a multi-protein ubiquitination system will
likely shed light on other approaches that can be used
to inhibit the E3 ubiquitin ligase activity of MDM2.
We had started to access the effects of a
disordered pseudo-substrate motif [54] in the N-
terminal domain of MDM2 on its ubiquitin ligase
function to determine how this might regulate its
ubiquitin ligase function. One model using NMR
proposed that the phosphomimetic mutation (Asp17)
would stabilize the pseudo-substrate motif similar to
a lid over the peptide-binding pocket and inhibit
MDM2 binding to p53 [32]. However, biochemical
analysis of full-length MDM2 with mutation at Asp17
indicated that this mutation increases the specific
activity of full-length MDM2 as an E3 ubiquitin ligase
[36] and also that the isolated N-terminal domain has
an elevated thermostability through Asp17 mutation
[38]. These latter data suggest that the Asp17
mutation does not necessarily sterically occlude
the peptide-binding pocket of MDM2 and “inhibit”
MDM2 binding to p53. Thus, the function of the lid
and the effects of its phosphorylation are not
understood mechanistically. Further analysis of this
mutant as a tool to dissect allostery in MDM2 is
summarized in this study where we use physiolog-
ical, cell-based, and in vitro assays to dissect
mechanisms of how the Asp17 mutation in MDM2
can stimulates its biochemical function.
Four new insights have been gained on the
biochemical nature of full-length MDM2 from this
report. First, lid deletion not only thermally destabi-
lizes the isolated N-terminal domain of MDM2
(amino acids 1–126) [38] but reduces the intrinsic
fluorescence toward a blue-shifted wavelength
(Fig. 4). This suggests that the lid either directly
binds to the central domain that contains all four
tryptophan residues or allosterically alters this
domain. Given that a motif in the central domain ofMDM4 interacts in an inter- or intra-molecular
interaction with the hydrophobic pocket of MDM4
[31,55], it might be that the MDM2 lid directly binds
the central domain. However, it is interesting that the
Asp17 mutation does not induce a change in intrinsic
fluorescence, at least suggesting that the phosphor-
ylated lid does not necessarily induce binding of the
lid to the central domain.
A second insight on the effects of the lid on MDM2
conformation was based on the creation of the
Phe235-MDM2 mutant in MDM2. This mutation
results in an MDM2 protein where the zinc finger
(containing all three remaining tryptophan residues)
presumably is the source of the intrinsic fluores-
cence. The deletion of the MDM2 lid induces the
same 4-nm blue shift in the fluorescence localizing
the effects of the lid on MDM2 conformation to at
least the zinc-finger motif. In addition, this produces
a very specific change in the interaction of the MDM2
zinc motif with its environment and a protein with an
enhanced activity in binding to p53. Thus, the lid
regulates the conformation of the zinc domain and
this has an impact on the activity of MDM2 as a
p53-binding protein. However, this creates a mutant
MDM2 protein with apparently identical ubiquitin
ligase activity to wt-MDM2 (Fig. 6). Thus, we have
been able to uncouple the binding of MDM2 to p53
from increases in its E3 ubiquitin ligase activity
induced by Asp17 mutation.
The third advance is a novel effect of the Asp17
mutation on a p53-independent function of MDM2.
We ruled out an effect on the central domain
conformation using intrinsic fluorescence assays
(Figs. 4 and 5) but identified a stimulation on the
“discharge” of the E2-ubiquitin conjugate (Fig. 7).
These data identify an unexpected effect of the “lid”
phosphorylation mutation on MDM2 function. An
emerging view of low-affinity/weak peptide motif
interactions is that they play an important role in the
regulation of the many distinct and dynamic protein–
protein interactions [56]. This was shown quantita-
tively with prior reports that the lid mutation (S17D)
can induce thermostability of the isolated N-terminal
domain of MDM2. In our current manuscript, we
show that the S17D mutation does not induce a
change in the intrinsic fluorescence of the central
domain (as does “lid” deletion). Rather, this mutation
can induce this unexpected ability of MDM2 to
catalyze the discharge of ubiquitin from E2 in the
absence of p53. Thus, there is a novel protein–
protein contact site for MDM2—presumably with E2
and/or ubiquitin that drives this dissociation. Further
dissection of this E3:E2-ubiquitin complex will shed
light on the dynamics of this aspect of the MDM2-ca-
talyzed reaction cycle.
A final insight has been gained on the possible
physiological effects of the lid phosphorylation on
MDM2 regulation in cells. Having identified that
phosphorylation of the MDM2 lid at Ser17 most
1743A Disordered Pseudo-Substrate Motif in MDM2dominantly occurs, not after stresses such as DNA
damage where most of our knowledge lies on the
MDM2-p53 axis, but in response to a change in cell
density, suggests a tumor-relevant role for this signal.
The high cell density in human solid cancers would
then presumably drive enhanced phosphorylation of
MDM2 at the lid and in turn result in enhanced
turnover of MDM2 (Fig. 1) that in turn can destabilize
p53 (Fig. 1). This might be one mechanism whereby
p53 activity is attenuated byhigh cell density [42]. If so,
then strategies could be developed in the future that
inhibit the “lid kinase” ofMDM2as away to rescue p53
function.Experimental Procedures
Chemicals, antibodies, peptides, plasmids,
and proteins
All chemicals were acquired from Sigma-Aldrich
unless indicated otherwise. Monoclonal antibodies
targeting MDM2 (2A10, 4B2) and p53 (DO-1) or
polyclonal antibodies to MDM2 and p53 (CM-1)
antibodies were reported previously [21]. The anti-
bodies FK1 and FK2 were obtained from Millipore
and were used to detect ubiquitin chains; the anti-
polyhistidine tag mAb was obtained from Novagen.
Antibodies were used at a dilution of 1:5000 for
immunoblotting or 1:1000 for coupled protein–
protein interaction assays unless otherwise stated.
N-terminal biotinylated peptides were obtained from
Mimotopes Pty., Ltd. (Clayton, Australia) and dis-
solved in Me2SO.
Phospho-Ser17-specific mAb generation
and characterization
Hybridomas generated from immunization of a
KLH-conjugated synthetic peptide according to
protocols form Harlow and Lane [57] using the
amino acid sequence 14-VTT(S-phospho 17)
QIPAS-22 derived from the human MDM2 lid.
Monoclonal antibodies were purified from ascites
fluid using a Protein-G column, eluted using 0.1 M
glycine (pH 2.5), and dialyzed against phosphate-
buffered saline (PBS). The mAb characterized in this
report (EW1012) was used in all figures as indicated
at a final concentration of 1 μg/ml (Fig. 1a–c).
Biotinylated peptides used to define the epitope of
EW102 were obtained from Chiron and suspended
in DMSO at a concentration of 5 mg/ml. Polystyrene
plates (Costar) were coated overnight at 1 μg/ml
streptavidin in de-ionized water. After overnight incu-
bation and blocking with 3% bovine serum albumin
(BSA)/PBS-Tween-20 (0.1%), the wells were incubat-
ed with the indicated MDM2 lid peptide at a concen-
tration of 1 μg/ml. Following extensive washing, weadded EW102 for 1 h at 1 μg/ml in 3% BSA/PBS-
Tween-20 (0.1%), and the bound mAb was detected
using horseradish peroxidase (HRP)-conjugated
anti-mouse antibody (DAKO) and ECL solution and
was analyzed using anAscent Fluoroskan plate reader
(Labsystems) at 450 nm.
Epitope mapping of the phospho-Ser17-specific
mAb
PurifiedmAbwasprocessedusinga12-mer peptide-
phage combinatorial library by coating the mAb
overnight at 1 μg/ml in 0.1 M NaHCO3 (pH 9.0). After
blocking with 3% BSA/PBS-Tween-20 (0.1%), we
incubated thewellswith the stock peptide-phage library
(12-mer library; New England Biolabs) [5 μl/100 μl of
3% BSA/PBS-Tween-20 (0.1%)] and indicated for 1 h
at room temperature. The wells were washed with 3%
BSA/PBS-Tween-20 (0.1%) to elute non-specifically
bound phage and eluted using 0.1 M glycine (pH 2.5).
The phage pools were added to exponentially growing
bacteria to propagate the phage. The biopanning
was repeated three times according tomanufacturer's
protocol and the insert peptides were sequenced
using recommended primers.
Cell culture
A375 or HCT116 cells were grown at 37 °C in
Dulbecco's modified Eagle's medium or RPMI with
10% fetal bovine serum and 5% CO2. Transient
transfections of the MDM2 alleles were carried out
as previously described [29]. Upon reaching 40–
100% confluency, we transfected the cells by means
of Lipofectamine™ 2000 (Invitrogen) reagent with the
total amount of DNA for all wells kept constant and
including pcDNA3.1, pcDNA3.1-wt-MDM2, pcDNA3.1-
Asp17-MDM2, and pcDNA3.1-EGFP. Twenty-four
hours post-transfection, the cells were washed once
in ice-cold PBS and lysed with lysis buffer [8 M urea,
50 mM Hepes (pH 8.0), 1 mM dithiothreitol (DTT),
0.1 M KCl, 1 mM benzamidine, 10 mM NaF, and 1%
Triton-X100]. Protein concentrations were determined
using the method of Bradford [58].
Protein purification
wt-MDM2, ΔLID-MDM2, Phe235-MDM2, Asp17-
MDM2, and the double mutant ΔLID-Phe235-MDM2
tagged with glutathione S-transferase were
expressed in BL21λDE3 and isolated from bacterial
lysates using GSH agarose (GE Healthcare) affinity
chromatography and untagged MDM2 was generated
by cleavingwithPreScissionprotease (GEHealthcare)
as previously described [38]. His-tagged E2 ubiquitin
ligase, UBCH5a, was expressed and purified using
NTA affinity chromatography. Human p53 protein
was expressed in Sf9 insect cells and was purified
from soluble lysates using heparin (GE Healthcare)
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a linear gradient of 0–1 M NaCl in Buffer A [10%
glycerol, 25 mM Hepes (pH 8.0), 1 mM DTT, and
1 mM benzamidine]. Native p53 conformation was
determined using conformation-specific monoclonal
antibodies PAB240 and PAB1620 as reported previ-
ously [21]. Full-length wt, Ala269-p53, or Asp269-p53
[46] was translated in vitro using the TnT T7-coupled
reticulocyte lysate system (Promega). Coupled
transcription/translation was carried out at 30 °C for
90 min according to the manufacturer's protocol,
using pcDNA p53 wt, Ala269-p53, or Asp269-p53 as
DNA templates and the translated products were
analyzed by SDS-PAGE and immunoblotting, as we
reported previously [21].
In vitro ubiquitination assays
Ubiquitination reactions (21 μl) were performed in
25 mM Hepes (pH 8); 10 mM MgCl2; 0.25 mM DTT;
0.5 mM benzamidine; 0.05% Triton X-100; 4 mM
ATP; 10 mM phosphocreatine; 3.5 U/ml creatine
kinase; 2 μg ubiquitin (Boston Biosciences) containing
25 ng UBE1 (E1; Boston Biosciences), 80 ng
UBCH5a (E2), and 50 ng E3 (MDM2 wt and the
indicated mutant variants) unless otherwise stated;
and approximately 100 ng purified p53 and/or 50 μM
peptide where indicated. Reactions were initiated by
addition of MDM2 and incubated at 30 °C for 15 min
before reactions were terminated with reducing SDS
sample buffer and analyzed using 4–12% NuPAGE
gels in Mops buffer (Invitrogen) followed by immuno-
blotting with DO-1 to measure changes in p53
ubiquitination. For analysis of E2-ubiquitin thioester
hydrolysis (e.g., ubiquitin discharge), reactions (20 μl)
containing 25 mM Hepes (pH 8.0), 10 mM MgCl2,
0.25 mM DTT, 0.5 mM benzamidine, 0.05% Triton X,
2 μg ubiquitin, 100 μM ATP, 25 ng UBE1, and 80 ng
UBCH5a were assembled and incubated for 5 min at
30 °C to form the covalent UBCH5a-ubiquitin interme-
diate. After 30 min, 50 ng wt-MDM2 wt or Asp17-
MDM2was added and reactions were incubated for up
to 30 min at 30 °C. For reactions in the presence of p53
orUBCH5apeptides,MDM2was incubatedwith p53or
peptide for 5 min at room temperature prior to addition
to the ubiquitin-charged UBCH5a reaction mix. Reac-
tions were terminated with non-reducing SDS sample
buffer containing 10 mM N-ethyl maleimide and the
ubiquitin charge status of the His-tagged UBCH5a
protein was detected by immunoblotting using anti-His
mAb at 1:2000 dilution.
Protein–protein interaction assays
MDM2 binding to UBE1, UBCH5A, and p53 was
assayed using polystyrene solid-phasemicrotiter wells
as previously described [36]. For UBE1, UBCH5a, and
p53 binding assays, plates were coated with 250 ng
UBE1, UBCH5a, or p53 in 0.1 M NaHCO3 (pH 9.0).After blocking with 3% BSA/PBS-Tween-20 (0.1%),
we titrated and incubated an MDM2 (from 250 to
3.9 ng) at room temperature for 1 h. After washing,
we detected bound MDM2 binding activity using 2A10
mAb, HRP-conjugated anti-mouse antibody, and ECL
solution and we quantified it using an Ascent Fluor-
oskan plate reader (Labsystems) at 450 nm. MDM2
binding to UBCH5a peptides was also determined as
follows: streptavidin-coated wells (1 μg/ml in deionized
water) were incubated with 5 μg 15-mer of overlapping
biotinylated UBCH5a peptides [in 3% BSA/PBS-
Tween-20 (0.1%)] for 1 h at room temperature and
then blocked with 3% BSA/PBS-Tween-20 (0.1%) and
incubated with 250 ng of MDM2 per well. After
washing, we detected bound MDM2 using 2A10 mAb
and ECL as described above. MDM2 binding to p53
peptides was determined as follows: the wells were
adsorbedwith streptavidin (1 μg/ml in deionized water)
overnight and washed using PBS, and biotinylated
peptides were added for 1 h followed by increasing
amounts of MDM2. Following a further 6× washes with
PBS-T, we incubated wells with secondary rabbit anti-
mouse HRP antibodies followed by further washing
andECL. The results were quantified using Fluoroskan
Ascent FL equipment (Labsystems) and analyzed with
Ascent Software version 2.4.1 (Labsystems). Peptides
BOX-Ia, BOX-Ib, BOX-Va, and BOX-Vb were from
Chiron Mimotopes and Nutlin-3a was from Alexis
Biochemicals. Peptide sequences are as follows:
BOX-Ia-Biotin-SGSGPPLSQETFSDLWKLLP,
BOX-Ib-Biotin-SGSGMPRFMDYWEGLN, BOX-Va-
Biotin-SGSGRNSFEVRVCACPGRD, and BOX-Vb-
Biotin-SGSGDQIMMCSMYGICKVKNIDLK. To deter-
mine the type of ubiquitin chain formed on p53 by
MDM2, we captured ubiquitinated p53 by polyclonal
p53 antibody CM-1 and analyzed it using ubiquitin
specific antibodies FK1 or FK2. Wells were coated
with 1:1000 dilution of polyclonal p53 antibody, CM-1,
in 0.1 M NaHCO3 overnight at 4 °C and were blocked
with 3% BSA/PBS-Tween-20 (0.1%). Ubiquitination
reactions containing p53 and MDM2 wt or S17D-
MDM2 were performed as described above and
added to the CM-1-coated wells and incubated for
2 h at room temperature to capture p53. Ubiquitina-
tion reactions lacking E3 ligase were used as a
control. After washing, we detected the presence of
monoubiquitin or monoubiquitin and polyubiquitin
chains using FK1 or FK2 monoclonal antibodies,
respectively, HRP-conjugated secondary antibody,
and ECL.
Intrinsic fluorescence assay
Fluorescence emission spectra of theMDM2 protein
isoforms were recorded on a Spex Fluoromax-3
spectrofluorometer. The bandwidths for excitation
and emission were set at 5 nm, and the excitation
wavelength was 295 nm. Fluorescence spectra
were recorded from 320 to 450 nm in 0.5-nm
1745A Disordered Pseudo-Substrate Motif in MDM2increments and a 1-s integration time. Experiments
were carried out at room temperature (15–21 °C) in
buffer containing: 25 mMHepes (pH 7.5), 50 mMKCl,
5% (v/v) glycerol, and 2 mM DTT. Proteins used
include wt-MDM2, ΔLID-MDM2, Phe235-MDM2,
Asp17-MDM2, and ΔLID-Phe235-MDM2 at final con-
centrations of 1 μM in a 0.5-ml final volume. Spectra
recorded represent the average of three emission
scans subtracted from the average of the three blank
(buffer only) scans.
Plasmids and site-directed mutagenesis
wt-MDM2 and ΔLID-MDM2 were cloned into the
Invitrogen Gateway system entry vector pDONR221
(Invitrogen) using the following primers: full-length
MDM2 Fwd 5′-GGGGACAAGTTTGTACAAAAAAG-
CAGGCTTCGAAGGAGATAGAACCAT GTGCAATA
CCAACATGTCTGTACCTACT-3′ and Rev 5′-
GGGGACCACTTTGTACAAGAAAGCTGGGTCC-
TAGGGGAAATAAGTTAGCACAATCAT-3′: lid dele-
tion MDM2 Fwd 5′-GGGGACAAGTTTGTACAA
AAAAGCAGGCTTCGAAGGAGATAGAACCAT-
GACCCTGGTTAGACCAAAGCCATTGCTT-3′ and
Rev same as full-length MDM2. This vector was used
as a template to perform site-directed mutagenesis
using the in vitro mutagenesis system QuikChange
(Stratagene) as directed by the manufacturer. MDM2
Ser17 was mutated to an aspartic acid using the
following primers (bases that introduce amino acid
change are in boldface): amino acid 17S N D Fwd
5′-GGTGCTGTAACCACCGACCAGATTCCAGC
TTCG-3′ and Rev 5′-CGAAGCTGGAATCTG
GTCGGTGGTTACAGCACC-3′. MDM2 Trp235 to
Phe235 was mutated using the following primers
(bases that introduce amino acid change are in
boldface): Fwd 5′-GTGAACATTCAGGTGATTCTTG-
GATCAGGATT-3′ and Rev 5′ AATCCTGATCCAA
GAAATCACCTGAATGTTCAC-3′. For native expres-
sion of protein in Escherichia coli, pDONR221-MDM2
vectors were recombined with the pDEST14 vector
(Invitrogen) as recommended by the manufacturer.
For expression in mammalian cells, the pDONR-
MDM2 vectors were recombined with the pDEST3.2
vector (Invitrogen). pDONR221-MDM2was used as a
template to PCR clone ΔLID-MDM2 into pCDNA3.1
with EcoR1 and Xho1 restriction sites. EcoR1 Fwd
primer 5′-GCCTCGAATTCATGACCCTGGTTA-
GACCAAAGCCATTGCTT-3 ′ and Xho1 Rev
5′-GCCTCGAGCTCCTAGGGGAAATAAGTTAGCA-
CAATCAT-3′. pCDNA3.1 full-length MDM2 was
subjected to site-directed mutagenesis as described
before to introduce mutation at Ser17.Funding
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